← All medicines

Withdrawn and historical medicines

Panobinostat (historical U.S. approval)

Independent educational summary · Sources checked November 20, 2026

Historical reference: panobinostat was used in combination treatment for previously treated multiple myeloma. FDA withdrew U.S. approval in March 2022 after the sponsor requested withdrawal because required confirmatory trials were not feasible.

Profile scope: Panobinostat (historical U.S. approval). Confirm the exact product and route; formulations and combination products are not interchangeable.

Possible side effects

Weight loss, headache, and digestive symptoms were reported.

Serious risks and warning signs

Severe diarrhea with dehydration and life-threatening heart problems were major warnings. Significant bleeding, infection, and liver symptoms also needed urgent assessment. This historical summary does not imply current U.S. approval or routine availability.

A question for your healthcare team

If an older record lists this drug, what follow-up is relevant and which currently approved alternatives are appropriate?

What to do with this information

Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.

Sources

Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.